Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577928 · ClinicalTrials.gov registry record
Value of Fecal Calprotectin
A clinical trial of Inflammatory Bowel Disease and Calprotectin, sponsored by Indiana University.
- Completed
- Registry status
- 171
- Enrollment target
- 1
- Study location
NCT00577928 is a study of Inflammatory Bowel Disease and Calprotectin that has completed, run by Indiana University. The registered enrollment target is 171 participants, below the 398-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00577928, a study of Inflammatory Bowel Disease and Calprotectin, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 171 participants
- Enrollment target
- 1
- Study location
Study Summary
For the main goal - the accuracy of calprotectin for the diagnosis of IBD - calprotectin levels will be compared between patients with and without a diagnosis of IBD and the sensitivity, specificity and accuracy will be determined. For the secondary aim - the correlation between calprotectin levels and disease activity - in patients with IBD selected from this cohort, we will determine the association between calprotectin levels and clinical IBD score, serological markers (WBC, Hgb, Platelets, ESR, CRP, Albumin), endoscopic (disease score, pathological activity) and radiological features (bowel wall thickening, enhancement, edema, mesenteric inflammation).
Conditions Studied
Study Locations (1)
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577928
The ClinicalTrials.gov registry entry for NCT00577928 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 398-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (57% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammatory Bowel Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00577928 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00577928 about?
NCT00577928 is a clinical study titled "Value of Fecal Calprotectin". For the main goal - the accuracy of calprotectin for the diagnosis of IBD - calprotectin levels will be compared between patients with and without a diagnosis of IBD and the sensitivity, specificity and accuracy will be determined. For the secondary aim - the correlation between calprotectin levels ...
What is the current status of trial NCT00577928?
This trial is currently completed. The enrollment target is 171 participants. The study started on 2006-04. Estimated completion is 2011-12.
What conditions does trial NCT00577928 study?
This clinical trial studies the following conditions: Inflammatory Bowel Disease, Calprotectin.
Who is sponsoring clinical trial NCT00577928?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00577928 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Morning Light Therapy in IBD
RECRUITING · NA
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
RECRUITING
-
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
RECRUITING
-
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.